Adalimumab-adbm Kit
Product Images NDC 82009-150

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Adalimumab-adbm (NDC 82009-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Adalimumabqt 01)

A line graph showing the percent of ACR 20 responders over time in weeks, comparing two groups: one receiving 40 mg of Adalimumab-adbm every other week and a placebo group. The graph tracks response rates up to 48 weeks, with the Adalimumab-adbm group consistently showing higher responder percentages than the placebo group.*

FDA Label Image

Figure 2 (Adalimumabqt 02)

A line graph showing % ASAS 20 Response over time (weeks) for two groups: Adalimumab (N=208) and Placebo (N=107). The Adalimumab group shows a rapid increase in response up to week 8-10, plateauing above 50%, while the Placebo group shows a lower and gradually increasing response below 20% across 24 weeks.*

FDA Label Image

Figure 3 (Study UV I)

A line graph depicting treatment failure rates (%) over time in months, comparing Adalimumab treatment against placebo. The graph shows treatment failure rate on the vertical axis and time from 0 to 20 months on the horizontal axis, with separate lines for placebo and Adalimumab, demonstrating lower failure rates for Adalimumab over time.*

FDA Label Image

Figure 3 (Study UV II)

A line graph showing treatment failure rate (%) over time in months for Adalimumab compared with placebo. The x-axis represents time up to 20 months, and the y-axis shows treatment failure rate from 0 to 100%. Two lines depict treatment failure rates for placebo and Adalimumab groups, with numbers at risk displayed below the timeline.*

FDA Label Image

Image (Adalimumabqt 05)

An instructional diagram of an Adalimumab-adbm prefilled injection pen. The image labels parts of the pen including the injection button, grip, medicine window, tip with needle guard, plunger inside, and removable cap, illustrating the device components for administration.*

FDA Label Image

Step 1 (Adalimumabqt 06)

An instructional illustration showing components of a drug administration kit for Adalimumab-adbm, including an injection device (a), a red biohazard sharps container (b), an alcohol prep pad (c), and an adhesive bandage (d).*

FDA Label Image

Step 2 (Adalimumabqt 07)

An instructional illustration showing parts of a medicine pen or injector. It highlights the area where the medicine is visible inside the device and indicates where to find the expiration date labeled as 'EXP YYYY-MMM' on the pen.*

FDA Label Image

Step 3 (Adalimumabqt 08)

An instructional illustration showing hands being washed under running water from a faucet with soap bubbles visible, indicating proper hand hygiene.*

FDA Label Image

Step 4 (Adalimumabqt 09)

An instructional illustration showing appropriate injection sites for a medication on a seated human figure. The diagram highlights the abdomen and thighs as recommended areas for injection.*

FDA Label Image

Step 5 (Adalimumabqt 10)

Illustration showing a hand pouring a packet or sachet onto a flat surface indicated with a dotted line circle, suggesting preparation or use of a product component likely related to a dosing or assembly instruction.*

FDA Label Image

Step 6 (Adalimumabqt 11)

An instructional illustration showing a person's hand removing the cap from a green and white tube, likely part of a medication administration kit, depicting the preparation step for dispensing the medication.*

FDA Label Image

Step 7 (Adalimumabqt 12)

Illustration showing a hand squeezing the skin around an injection site on an arm, with a label pointing to the injection site area.*

FDA Label Image

Step 8 (Adalimumabqt 13)

An instructional illustration showing how to use a pen injector. It depicts a hand holding the pen vertically at a 90-degree angle above the skin, with the thumb pressing and holding the top of the device while the tip touches the injection site. The inset highlights the pen tip and the action of pressing and holding during injection.*

FDA Label Image

Step 9 (Adalimumabqt 14)

An instructional illustration showing how to use an injection pen for Adalimumab-adbm kit. It depicts a hand holding the pen against the skin with an arrow indicating to press the injection button, hold the pen against the skin, and slowly count to 10. A close-up inset highlights the plunger component of the pen.*

FDA Label Image

Step 10 (Adalimumabqt 15)

An instructional illustration showing a hand holding an Adalimumab-adbm injection pen positioned to administer a subcutaneous injection into the skin of another person's forearm. A close-up inset highlights the injection pen's needle area with an arrow indicating the direction to press down for injection.*

FDA Label Image

Step 10 (Adalimumabqt 16)

An illustration showing a hand pressing a cotton ball or pad onto the skin, likely demonstrating a step in preparation or aftercare for an injection or similar procedure.*

FDA Label Image

Step 11 (Adalimumabqt 17)

Illustration showing a hand disposing of a pen-like device, possibly a syringe or injector, into a red biohazard sharps container with a lid. The container features a black biohazard symbol, indicating safe disposal of medical sharps.*

FDA Label Image

Image (Adalimumabqt 18)

An instructional diagram of a syringe showing labeled parts: plunger rod, grip, plunger, medicine, needle, and cap. The illustration visually identifies each component of the syringe used in the administration of medication.*

FDA Label Image

Step 1 (Adalimumabqt 19)

An instructional illustration showing equipment for injection preparation. It includes a syringe (a), a red biohazard sharps disposal container (b), a cotton ball or gauze pad (c), and an alcohol prep pad (d). The items are labeled a through d, indicating steps or components related to injection administration.*

FDA Label Image

Step 2 (Adalimumabqt 20)

An illustration showing a syringe labeled with 'Medicine' pointing to the medicine inside it and an adjacent circle highlighting where to find the 'Expiration date' printed as 'EXP YYYY-MMM' on the syringe. This image demonstrates how to identify the medicine area and expiration date on the syringe.*

FDA Label Image

Step 3 (Adalimumabqt 21)

An illustration showing hands under running water with soap bubbles, depicting a handwashing procedure. The image highlights the steps of cleansing hands thoroughly with soap and water.*

FDA Label Image

Step 4 (Adalimumabqt 22)

An instructional illustration showing common injection sites for a medication. The diagram of a seated person highlights the abdomen and thighs as preferred areas for injection, with dashed circles indicating specific locations on these body parts.*

FDA Label Image

Step 5 (Adalimumabqt 23)

An instructional illustration showing a hand pinching and lifting the skin on an arm, preparing for a subcutaneous injection. The image demonstrates the proper technique for administering a medication injection under the skin, relevant for patients using Adalimumab-adbm kits.*

FDA Label Image

Step 6 (Adalimumabqt 24)

An instructional illustration showing hands removing a cap from a syringe. The syringe is held in the right hand, with the needle exposed as the cap is pulled away toward the left hand.*

FDA Label Image

Step 7 (Adalimumabqt 25)

An instructional illustration showing a hand squeezing and holding the skin around an injection site, with an arrow and text indicating 'Squeeze around injection site and hold.' This diagram is likely part of guidance for administering an injection.*

FDA Label Image

Step 8 (Adalimumabqt 26)

An instructional diagram showing how to insert a needle at a 45-degree angle into the skin of the forearm. The image depicts one hand holding the skin taut and the other hand inserting the needle with an arrow indicating the angle of insertion.*

FDA Label Image

Step 9 (Adalimumabqt 27)

An instructional illustration showing a hand slowly pushing the plunger rod of a syringe to administer an injection. A close-up inset highlights the plunger and needle tip at the injection site.*

FDA Label Image

Step 10 (Adalimumabqt 28)

Instructional illustration showing a hand removing a needle from an injection site at a 45-degree angle. The image demonstrates needle removal technique following an injection, indicating angle and hand positioning on the skin.*

FDA Label Image

Step 10 (Adalimumabqt 29)

An instructional illustration showing a hand using a cotton ball or gauze to press on the skin, likely as a step in preparing the injection site for the Adalimumab-adbm kit.*

FDA Label Image

Step 11 (Adalimumabqt 30)

An instructional illustration showing a hand disposing of a syringe into a red biohazard sharps container. The container is designed for safe disposal of medical sharps and features a biohazard symbol on the front.*

FDA Label Image

Principal Display Panel (Kit Carton)

Adalimumab-adbm PEN Injection kit label featuring 40 mg/0.8 mL strength for subcutaneous use only. The label shows the product name, dosage, and specifies that it contains 2 single-dose prefilled pens. The packaging is from Quallent Pharmaceuticals Health LLC and includes a visual of the prefilled pen device.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Adalimumab-adbm PEN injection, 40 mg/0.4 mL, a subcutaneous use only kit containing 2 single-dose prefilled pens. The label features the product name, strength, dosage form, and manufacturer Quallent Pharmaceuticals Health LLC. It includes an image of the prefilled injection pen in white and green colors and instructions directed to pharmacists regarding dispensing and medication guide inclusion.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Adalimumab-adbm injection 40 mg/0.4 mL prefilled syringes by Quallent Pharmaceuticals Health LLC. The label indicates a kit containing 2 single-dose prefilled syringes for subcutaneous use. The label includes images of the prefilled syringes and states the product is prescription only.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for Adalimumab-adbm Injection, 40 mg/0.8 mL kit by Quallent Pharmaceuticals Health LLC. The box contains 2 single-dose prefilled syringes for subcutaneous use only. The label features the product name, dosage strength, and syringe images, along with usage and pharmacist attention notices.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.